UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Autoimmunity reviews, 2017-06, Vol.16 (6), p.658-665

2017

Volltextzugriff (PDF)

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Neurology, 2015-07, Vol.85 (2), p.177-189

2015

Volltextzugriff (PDF)

Safety of Tocilizumab in the Treatment of COVID-19-Related Longitudinally Extensive Transverse Myelitis

Canadian journal of neurological sciences, 2024-05, Vol.51 (3), p.466-468

2024

Volltextzugriff (PDF)

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

Brain (London, England : 1878), 2019-07, Vol.142 (7), p.1858-1875

2019

Volltextzugriff (PDF)

Brain health: time matters in multiple sclerosis

Multiple sclerosis and related disorders, 2016-09, Vol.9, p.S5-S48

2016

Volltextzugriff (PDF)

Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study

The Lancet (British edition), 2014-01, Vol.383 (9912), p.138-145

2014

Volltextzugriff (PDF)

An atlas for human brain myelin content throughout the adult life span

Scientific reports, 2021-01, Vol.11 (1), p.269-269, Article 269

2021

Volltextzugriff (PDF)

Goodpasture’s Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis

Canadian journal of neurological sciences, 2018-11, Vol.45 (6), p.712-714

2018

Volltextzugriff (PDF)

Inter-Vendor Reproducibility of Myelin Water Imaging Using a 3D Gradient and Spin Echo Sequence

Frontiers in neuroscience, 2018-11, Vol.12, p.854-854

2018

Volltextzugriff (PDF)

Nuclear Receptor NR1H3 in Familial Multiple Sclerosis

Neuron (Cambridge, Mass.), 2016-10, Vol.92 (2), p.555-555

2016

Volltextzugriff (PDF)

Case-Control Studies Are Not Familial Studies

Neuron (Cambridge, Mass.), 2016-10, Vol.92 (2), p.339-341

2016

Volltextzugriff (PDF)

Comparison of multi echo T2 relaxation and steady state approaches for myelin imaging in the central nervous system

Scientific reports, 2021-01, Vol.11 (1), p.1369-1369, Article 1369

2021

Volltextzugriff (PDF)

Analysis of NOD-like receptor NLRP1 in multiple sclerosis families

Immunogenetics (New York), 2018-03, Vol.70 (3), p.205-207

2018

Volltextzugriff (PDF)

Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort

Frontiers in neurology, 2021-01, Vol.11, p.525933-525933

2021

Volltextzugriff (PDF)

Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis

Frontiers in neurology, 2023-05, Vol.14, p.1165267-1165267

2023

Volltextzugriff (PDF)

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression

Multiple sclerosis journal - experimental, translational and clinical, 2019-10, Vol.5 (4), p.2055217319885983-2055217319885983

2019

Volltextzugriff (PDF)

The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design

BMC neurology, 2021-10, Vol.21 (1), p.1-418, Article 418

2021

Volltextzugriff (PDF)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420982134-1756286420982134

2021

Volltextzugriff (PDF)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a

NeuroImage clinical, 2022-01, Vol.35, p.103109-103109, Article 103109

2022

Volltextzugriff (PDF)

The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241273045

2024

Volltextzugriff (PDF)

Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation

Multiple sclerosis and related disorders, 2018-02, Vol.20, p.37-42

2018

Volltextzugriff (PDF)

Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis

Neuron (Cambridge, Mass.), 2016-10, Vol.92 (2), p.331-332

2016

Volltextzugriff (PDF)

Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients

BMC neurology, 2019-07, Vol.19 (1), p.173-173, Article 173

2019

Volltextzugriff (PDF)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Therapeutic advances in neurological disorders, 2023-01, Vol.16, p.17562864231194823-17562864231194823

2023

Volltextzugriff (PDF)

1 – 25 von 276

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(247)
Mit Volltextzugriff
(175)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(117)
Life Sciences & Biomedicine
(104)
Multiple Sclerosis
(97)
Neurosciences & Neurology
(89)
Clinical Neurology
(75)
Humans
(55)
Magnetic Resonance Imaging
(52)
Neurosciences
(39)
Neurology
(25)
Neuroimaging
(24)
Mri
(19)
Patients
(19)
Radiology, Nuclear Medicine & Medical Imaging
(19)
Clinical Trials
(18)
Technology
(16)
Multiple Sclerosis - Pathology
(14)
Brain
(13)
Brain - Pathology
(13)
Lesions
(13)
Magnetic Resonance Imaging - Methods
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Safety of Tocilizumab in the Treatment of COVID-19-Related Longitudinally Extensive Transverse Myelitis

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

Brain health: time matters in multiple sclerosis

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study

An atlas for human brain myelin content throughout the adult life span

Goodpasture’s Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis

Inter-Vendor Reproducibility of Myelin Water Imaging Using a 3D Gradient and Spin Echo Sequence

Nuclear Receptor NR1H3 in Familial Multiple Sclerosis

Case-Control Studies Are Not Familial Studies

Comparison of multi echo T2 relaxation and steady state approaches for myelin imaging in the central nervous system

Analysis of NOD-like receptor NLRP1 in multiple sclerosis families

Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort

Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression

The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a

The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics

Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation

Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis

Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Aktive Filter

Suchergebnisse filtern